Aflibercept Provides Long-Term Benefit, No Safety Concerns for Patients With Diabetic Macular Edema: Presented at AAO

Doctor’s Guide -- CHICAGO -- October 22, 2010 -- The novel anti-vascular endothelial growth factor aflibercept is superior to laser therapy alone in treating clinically significant diabetic macular oedema, researchers stated here at the Annual Meeting of the American Academy of Ophthalmology (AAO).